14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ivabradine in sepsis

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sir, Persistent tachycardia in sepsis or multi-organ dysfunction syndrome (MODS) is an ominous sign.[1] This usually comes under control with judicious use of antibiotics, fluid resuscitation, sedation. Uncontrolled tachycardia in systemic inflammatory response syndrome and sepsis deprives the heart muscle of oxygen. As it progresses, insufficient heart muscle nutrition eventually leads to myocardial dysfunction. It can also present as heart failure, systolic heart failure or diastolic heart failure. In acute coronary syndromes, beta blockers are used to control heart rate. However in MODS, it cannot be used due to hemodynamic instability and worsened myocardial function. Sinoatrial (SA) myocytes are the pacemaker cells in the heart.[2 3] Pacemaker activity involves several ionic currents that influences spontaneous depolarization of SA node including If current. The word “f” means funny” because this current has unusual properties as compared with other currents known at the time of its discovery. If current is carried out by sodium and potassium ions across the sarcolemma. It is one of the most important ionic current for regulating pacemaker activity in SA node. Ivabradine is a If current inhibitor in SA node.[2 3] Currently, it is the only agent shown to clinically lower heart rate with no negative inotropism or effects on conduction and contractility.[2 3] Ivabradine selectively inhibits the pacemaker If current in a dose dependent manner at concentrations that do not affect other cardiac ion currents. Blocking this channel reduces cardiac pacemaker activity, slowing the heart rate and allowing more time for blood flow to the myocardium. The dosing is started at 5 mg twice daily, and if tolerated can be safely continued to 7.5 mg twice daily. Food delays the absorption of ivabradine. As metabolism involves cytochrome P4503A4 (CYP3A4), concurrent use of inhibitors of CYP3A4 (macrolide antibiotics, azole antifungals) is contraindicated. Metabolites are excreted in urine and feces. Main t ½ is 2 h (70-75% of area under the curve) in plasma and has an effective t ½ of 11 h. Total clearance is 400 ml/min and renal clearance is 70 ml/min. The various adverse effects of ivabradine includes luminous phenomenon (due to blockade of Ih channel in the retina, which resembles If cardiac channels), atrioventricular block, ventricular extrasystole and bradycardia.[3]

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Ivabradine – the first selective sinus node If channel inhibitor in the treatment of stable angina

          Summary Heart rate, a major determinant of angina in coronary disease, is also an important predictor of cardiovascular mortality. Lowering heart rate is therefore one of the most important therapeutic approaches in the treatment of stable angina pectoris. To date, β-blockers and some calcium-channel antagonists reduce heart rate, but their use may be limited by adverse reactions or contraindications. Heart rate is determined by spontaneous electrical pacemaker activity in the sinoatrial node controlled by the I f current. Ivabradine is the first specific heart rate-lowering agent that has completed clinical development for stable angina pectoris. It is selective for the I f current, lowering heart rate at concentrations that do not affect other cardiac ionic currents. Specific heart-rate lowering with ivabradine reduces myocardial oxygen demand, simultaneously improving oxygen supply. Ivabradine has no negative inotropic or lusitropic effects, preserving ventricular contractility, and does not change any major electrophysiological parameters unrelated to heart rate. Randomised clinical studies in patients with stable angina show that ivabradine effectively reduces heart rate, improves exercise capacity and reduces the number of angina attacks. It has superior anti-anginal and anti-ischaemic activity to placebo and is non-inferior to atenolol and amlodipine. Ivabradine therefore offers a valuable approach to lowering heart rate exclusively and provides an attractive alternative to conventional treatment for a wide range of patients with confirmed stable angina.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Pure heart rate reduction: The if channel from discovery to therapeutic targets

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Pure heart rate reduction: The if channel from discovery to therapeutic targets

                Bookmark

                Author and article information

                Journal
                J Anaesthesiol Clin Pharmacol
                J Anaesthesiol Clin Pharmacol
                JOACP
                Journal of Anaesthesiology, Clinical Pharmacology
                Medknow Publications & Media Pvt Ltd (India )
                0970-9185
                2231-2730
                Oct-Dec 2013
                : 29
                : 4
                : 570-571
                Affiliations
                [1]Department of Anesthesiology, Care Hospital, Banjara Hills, Axon Anesthesia Associates, Hyderabad, Andhra Pradesh, India
                Author notes
                Address for correspondence: Dr. Abhijit S Nair, Department of Anesthesiology, Care Hospital, Banjara Hills, Road No. 1, Hyderabad 500 034, India. E-mail: abhijitnair95@ 123456gmail.com
                Article
                JOACP-29-570
                10.4103/0970-9185.119154
                3819867
                24250010
                39445851-2ec3-4adf-a9f6-f0bd4c074396
                Copyright: © Journal of Anaesthesiology Clinical Pharmacology

                This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                Letter to Editor

                Anesthesiology & Pain management
                Anesthesiology & Pain management

                Comments

                Comment on this article